Genprex, Inc. (GNPX)

Market Cap	47.30M
Revenue (ttm)	n/a
Net Income (ttm)	-22.66M
Shares Out	51.97M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,106
Open	0.935
Previous Close	0.900
Day's Range	0.882 - 0.935
52-Week Range	0.736 - 2.670
Beta	-0.37
Analysts	Buy
Price Target	5.44 (+497.8%)
Earnings Date	Mar 29, 2023

About GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 29, 2018
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: GNPX

Analyst Forecast

According to 9 analysts, the average rating for GNPX stock is "Buy." The 12-month stock price forecast is $5.44, which is an increase of 497.80% from the latest price.

Price Target

$5.44

(497.80% upside)

Analyst Consensus: Buy